- Featured Product
- KD/KO Validated
PD-L1/CD274 Polyklonaler Antikörper
PD-L1/CD274 Polyklonal Antikörper für FC, IF, IHC, IP, WB, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, IP, IHC, IF, FC, CoIP, ChIP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 17952-1-AP
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
Erfolgreiche Detektion in WB | humanes Plazenta-Gewebe, A375-Zellen, HeLa-Zellen, HepG2-Zellen, humanes Herzgewebe, K-562-Zellen, Mausherzgewebe, Maus-Skelettmuskelgewebe, mit IFN-gamma behandelte A549-Zellen |
Erfolgreiche IP | Mausherzgewebe |
Erfolgreiche Detektion in IHC | humanes Tonsillitisgewebe, humanes Magenkrebsgewebe, Mausherzgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Erfolgreiche Detektion in IF | HEK-293-Zellen |
Erfolgreiche Detektion in FC | Raji-Zellen |
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
Western Blot (WB) | WB : 1:500-1:1000 |
Immunpräzipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
Immunhistochemie (IHC) | IHC : 1:300-1:1200 |
Immunfluoreszenz (IF) | IF : 1:10-1:100 |
Durchflusszytometrie (FC) | FC : 1:10-1:100 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
Produktinformation
17952-1-AP bindet in WB, IP, IHC, IF, FC, CoIP, ChIP, ELISA PD-L1/CD274 und zeigt Reaktivität mit human, Maus, Ratten
Getestete Reaktivität | human, Maus, Ratte |
In Publikationen genannte Reaktivität | human, Maus, Ratte |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Polyklonal |
Typ | Antikörper |
Immunogen | PD-L1/CD274 fusion protein Ag12432 |
Vollständiger Name | CD274 molecule |
Berechnetes Molekulargewicht | 290 aa, 33 kDa |
Beobachtetes Molekulargewicht | 45-56 kDa, 65-70 kDa |
GenBank-Zugangsnummer | BC074984 |
Gene symbol | CD274 |
Gene ID (NCBI) | 29126 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Antigen-Affinitätsreinigung |
Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis.
What is the molecular weight of PD-L1?
Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa).
What are the isoforms of PD-L1?
According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions.
What is the subcellular localization and tissue specificity of PD-L1?
It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues.
What is the function of PD-L1 in immune responses?
PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).
How can PD-L1's implication in cancer be used as a drug target?
In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).
Protokolle
Produktspezifische Protokolle | |
---|---|
WB protocol for PD-L1/CD274 antibody 17952-1-AP | Protokoll herunterladen |
IHC protocol for PD-L1/CD274 antibody 17952-1-AP | Protokoll herunterladen |
IF protocol for PD-L1/CD274 antibody 17952-1-AP | Protokoll herunterladen |
IP protocol for PD-L1/CD274 antibody 17952-1-AP | Protokoll herunterladen |
Standard-Protokolle | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Nat Biomed Eng Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. | ||
Adv Sci (Weinh) BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors | ||
Acta Pharm Sin B Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. | ||
Mol Cell Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. | ||
Mol Ther Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy | ||
Nat Commun WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. |